Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Active Biotech AB ( (SE:ACTI) ) has provided an announcement.
Active Biotech announced positive results from its Phase I LION study on laquinimod, an immunomodulatory eye drop, which will be presented at the AAO 2025 meeting. The study demonstrated that laquinimod was safe, well-tolerated, and reached therapeutically relevant concentrations in the eye, supporting its potential for treating inflammatory eye diseases. The company is now seeking a development partner for further clinical development.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs. The company has a portfolio that includes tasquinimod and laquinimod, which are small molecule immunomodulators in clinical development for hematological malignancies and inflammatory eye disorders, respectively. Active Biotech is also developing naptumomab, an anti-cancer immunotherapy, in partnership with NeoTX Therapeutics.
YTD Price Performance: 48.15%
Average Trading Volume: 8,322,878
Technical Sentiment Signal: Sell
Current Market Cap: SEK207.4M
For a thorough assessment of ACTI stock, go to TipRanks’ Stock Analysis page.